American Journal of Ophthalmology最新文献

{"title":"Clinical characteristics of patients with less common causes of Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy.","authors":"Vishanna Balbirsingh,Malena Daich Varela,Michel Michaelides","doi":"10.1016/j.ajo.2025.04.019","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.019","url":null,"abstract":"PURPOSETo analyse the clinical characteristics, natural history and genetics of Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy (LCA / EOSRD) associated with uncommon genes.DESIGNSingle tertiary referral centre retrospective case series.METHODSReview of clinical notes, ophthalmic images, and genetic testing results of 19 patients with disease-causing variants in genes which represent an unknown or <1% of all LCA/EOSRD cases: ALMS1, CABP4, KCNJ13, and OTX2.RESULTSSix patients were included with ALMS1-LCA, seven with CABP4, and three with OTX2 and KCNJ13, respectively. Nine previously unreported variants were identified. Disease and symptom onset was during early infancy in all patients, photophobia was seen in patients with ALMS1 and CABP4, while nyctalopia in KCNJ13 and OTX2. Across all groups, using the World Health Organization (WHO) visual impairment criteria, most patients (68%) were severely sight impaired at presentation and progressed to blind during follow-up. The worst vision was seen earliest in patients with ALMS1 and KCNJ13, with a mean of 2.2 and 2.8 LogMAR visual acuity in the second decade of life. Macular atrophy was present in all patients with KCNJ13 variants and peripheral retinal pigment deposits were also densest in KCNJ13, followed by OTX2. Patients with ALMS1 and CABP4 had minimal retinal deposition and adult patients with CABP4 had a foveal hyporeflective zone combined with generalized retinal involvement.CONCLUSIONSThe detailed genetic and phenotypic characteristics of patients with LCA due to four rare genes are described. Cross-sectional and longitudinal analysis contributes to our understanding of these rare diseases, aiming at improving patient diagnosis, prognostication, and management.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"19 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Comment on \"COVID-19 Vaccination and Ocular Adverse Events: A Self-Controlled Case Series Study From the Entire South Korean Population\".","authors":"Sungsoon Hwang,Se Woong Kang","doi":"10.1016/j.ajo.2025.04.026","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.026","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"135 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study: Ocular Adverse Events of Pegcetacoplan & Avacincaptad Pegol.","authors":"Zeena Kailani,Andrew Mihalache,Marko M Popovic,Peter J Kertes,Rajeev H Muni","doi":"10.1016/j.ajo.2025.04.022","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.022","url":null,"abstract":"OBJECTIVETo evaluate the post-marketing ocular adverse events (AEs) associated with avacincaptad pegol and pegcetacoplan, the only Food and Drug Administration (FDA)-approved treatments for geographic atrophy (GA).DESIGNRetrospective cohort study (pharmacovigilance analysis).SUBJECTSAE reports in the FDA Adverse Event Reporting System (FAERS) in which pegcetacoplan or avacincaptad pegol were identified as the primary suspect drugs were analyzed.METHODSUsing the OpenVigil 2.1 data mining software, we conducted a retrospective pharmacovigilance analysis of the FAERS database from inception to December 2024. We conducted disproportionality analyses to assess reporting odds ratios (RORs) for specific drug-AE combinations compared to all other drugs in the database.MAIN OUTCOME MEASURESOcular AEs.RESULTSA total of 752 and 80 patients with AEs secondary to pegcetacoplan and avacincaptad pegol, respectively, were identified. Ocular AEs disproportionately overreported for pegcetacoplan included anterior segment (iris) hemorrhage (ROR=1767, 95% CI=538 to 5803), iris neovascularization (ROR=1248, 95% CI=502 to 3099), choroidal neovascularization (ROR=1328, 95% CI=956 to 1845), intraocular injection complication (ROR=2552, 95% CI=1607 to 4053), hemorrhagic occlusive retinal vasculitis (ROR=4606, 95% CI=2000 to 10611), retinal occlusive vasculitis (ROR=2352, 95% CI=1313 to 4212), and bacterial endophthalmitis (ROR=1260, 95% CI=613 to 2589). Ocular AEs disproportionately overreported for avacincaptad pegol included choroidal neovascularization (ROR=1169, 95% CI=426 to 3205), vitritis (ROR=782, 95% CI=316 to 1936), dry age-related macular degeneration (ROR=684, 95% CI=316 to 1936), and cystoid macular edema (ROR=445, 95% CI=140 to 1412).CONCLUSIONSBased on current prescribing patterns, a broader spectrum of ocular AEs were reported for pegcetacoplan than avacincaptad pegol. These findings aim to enhance clinicians' understanding of the safety profiles of these agents, enabling informed patient care and heightened vigilance of these novel GA treatments.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"10 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence and Consensus-Based Imaging Guidelines in Multifocal Choroiditis with Panuveitis and Punctate Inner Choroiditis - Multimodal Imaging in Uveitis (MUV) Taskforce Report 5.","authors":"Sapna Gangaputra,Aniruddha Agarwal,Jeannette Ossewaarde-van Norel,Edmund Tsui,Jennifer E Thorne,Alejandra de-la-Torre,Michael Altaweel,Jyotirmay Biswas,Srinivas Sadda,Alessandro Invernizzi,Rupesh Agrawal,Jessica G Shantha,Massimo Accorinti,Amani Fawzi,Douglas A Jabs,David Sarraf,Vishali Gupta,","doi":"10.1016/j.ajo.2025.04.018","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.018","url":null,"abstract":"PURPOSETo develop imaging and consensus-based guidelines on the application of multimodal imaging in noninfectious multifocal choroiditis and panuveitis (MFCPU) and punctate inner choroiditis (PIC).DESIGNConsensus agreement guided by the review of literature and an expert committee using nominal group technique (NGT).METHODSAn expert committee applied a timed structured nominal group technique (NGT) to achieve consensus-based recommendations on specific disease characteristics, biomarkers of activity, and complications for MFCPU and PIC. Representative cases with non-infectious active and inactive MFCPU and PIC with color fundus photographs (CFP), optical coherence tomography (OCT), fundus fluorescein angiography (FFA), OCT angiography (OCTA), indocyanine angiography (ICGA), and fundus autofluorescence images (FAF) were reviewed. These recommendations were voted upon by the entire task force.RESULTSThe experts agreed that lesions of MFCPU and PIC can be well characterized using CFP. OCT is the preferred modality for detecting active lesions. Both FAF and OCT are effective for monitoring disease recurrence. Late-phase ICGA is most valuable in recurrent disease when the lesions are not visible on FAF and CFP. While OCTA and ICGA can successfully identify lesions and complications such as choroidal neovascularization, no imaging biomarkers were found to reliably distinguish between active and inactive lesions on these two modalities.CONCLUSIONSIncorporating imaging findings, particularly OCT, into the Standardization of Uveitis Nomenclature (SUN) classification criteria for MFCPU and PIC enables more precise assessment of disease activity. These consensus-based guidelines provide a framework for selecting optimal imaging modalities for diagnosis, monitoring and identification of complications of MFCPU and PIC.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"39 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Age and Underlying Etiologies on Outcomes of Strabismus Surgery in the Elderly Population.","authors":"Hilda Capó,Charlotte Tibi,Mariam S Vila-Delgado,Laura Huertas","doi":"10.1016/j.ajo.2025.04.023","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.023","url":null,"abstract":"PURPOSETo investigate the success of strabismus surgery in older adults and determine the impact of age and underlying etiology on surgical outcomes.METHODSRetrospective review of medical records of patients aged 60 years or older who underwent strabismus surgery at a tertiary eye care center. Surgical motor and sensory outcomes were analyzed.RESULTSOf the 562 that met criteria, patients were mostly female (56.1%) with a mean age of 71.7 ± 6.6 years. The majority of patients reported diplopia (85.9%). The most frequent etiologies were paralytic (27.9%), adult-onset esotropia (19.0%), and thyroid eye disease (16.4%). Following initial surgery, motor and sensory surgical success rates were 65.1% and 62.9%. No significant differences in mean age were observed based on sensory success (P=.8529), motor success (P=.1670), or etiology (P=.1069). Etiology was associated with motor and sensory success (P=.0160 and P=.0001, respectively). Adult-onset basic esotropia had higher rates of motor and sensory success (P=.0091), and convergence insufficiency exotropia and recurrent or consecutive strabismus had higher rates of sensory success (P=.0029 and P=.0393, respectively). Among demographic and pre-operative characteristics, etiology (P=.0008) predicted sensory success, and etiology (P=.0670) and use of adjustable sutures (P=.0003) predicted motor success. Patients who received adjustable sutures had significantly higher odds (OR = 2.15; 95% CI, 1.42-3.25) of motor success. Motor and sensory success rates improved to 78.1% and 73.3% after reoperation in 82 patients (14.6%).CONCLUSIONSEtiology was found to be predictor of sensory success, while both etiology and use of adjustable sutures were predictors of motor success. Surgical success was not influenced by increasing age.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"19 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two novel extended depth-of-focus intraocular lenses targeted for mini-monovision: a prospective randomized controlled trial.","authors":"Joukje C Wanten,Noël J C Bauer,Tos T J M Berendschot,Frank J H M van den Biggelaar,Rudy M M A Nuijts","doi":"10.1016/j.ajo.2025.04.024","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.024","url":null,"abstract":"PURPOSETo compare the visual outcomes of two extended depth-of-focus (EDOF) intraocular lenses (IOLs).DESIGNSingle-center prospective randomized controlled trial.METHODSPatients undergoing bilateral cataract surgery were randomly assigned to receive either the Acunex Vario IOL (Teleon Surgical B.V., Spankeren, The Netherlands) or the AcrySof IQ Vivity IOL (Alcon, Geneva, Switzerland); both Vario- and Vivity-group were targeted for mini-monovision. The primary outcome was the uncorrected intermediate visual acuity (UIVA, measured at 66cm). Secondary outcome parameters were uncorrected distance visual acuity (UDVA), uncorrected near visual acuity (UNVA), defocus curves, reading speed, contrast sensitivity, spectacle independence and quality of vision.SETTINGUniversity Eye Clinic, Maastricht University Medical Center+, the Netherlands.RESULTSA total of 31 subjects (62 eyes) were included, 16 patients were enrolled into the Vario-group and 15 patients into the Vivity-group. At three months postoperatively, no statistically significant differences were found for the binocular visual acuities between the groups after adjustment for covariates. The mean and standard deviation for the binocular UIVA was 0.04±0.11 and 0.15±0.11 logMAR (adjusted-P=0.264) for the Vario- and Vivity-group, respectively. The binocular UDVA was 0.00±0.14 and 0.08±0.10 logMAR (adjusted-P=0.753), and UNVA was 0.22±0.17 and 0.31±0.14 logMAR (adjusted-P=0.235), for both groups, respectively. While the Vario-group had a larger range of defocus, no significant differences were found for patient satisfaction and spectacle independence. Contrast sensitivity and reading speed were comparable, and there were no statistically significant differences in optical side effects between the groups.CONCLUSIONBilateral implantation of the Acunex Vario IOL and the AcrySof IQ Vivity IOL targeted for mini-monovision had comparable results for binocular visual acuity outcomes, contrast sensitivity, optical side effects, and reading speed. The Vario-group showed a larger continuous range of defocus.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"73 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.","authors":"Charles C Wykoff,Frank G Holz,Allen Chiang,David Boyer,Dilsher S Dhoot,Anat Loewenstein,Jordi Mones,Jeffrey Heier,Ashkan M Abbey,Lawrence J Singerman,Lejla Vajzovic,Jason Lin,Chao Li,Abhi Vilupuru,Caroline R Baumal,","doi":"10.1016/j.ajo.2025.04.016","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.016","url":null,"abstract":"PURPOSETo report 12-month results from the GALE open-label extension study (NCT04770545), evaluating up to 36 months of intravitreal pegcetacoplan treatment for geographic atrophy (GA) in age-related macular degeneration (AMD).DESIGNGALE is a prospective open-label extension study following the 24-month, sham-controlled, phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) studies of pegcetacoplan.PARTICIPANTSPatients with nonsubfoveal or subfoveal GA who completed OAKS, DERBY, or phase 1b APL2-103 (NCT03777332) studies.METHODSPegcetacoplan was administered monthly (PM) or every other month (PEOM) to all study eyes in GALE. Eyes receiving pegcetacoplan in OAKS and DERBY continued the same regimen (PM-PM and PEOM-PEOM), while eyes observed with sham in OAKS and DERBY crossed over to receive pegcetacoplan at the same dosing interval in GALE (SM-PM and SEOM-PEOM). Safety and efficacy through the first 12 months of GALE were assessed, reflecting up to 36 months of continuous pegcetacoplan treatment.MAIN OUTCOME MEASUREMean rate of change in GA area, total number of microperimetry scotomatous points, and adverse events.RESULTSThrough the first 12 months of GALE, 92.0% (727/790) patient retention was observed. Across all eyes, including eyes with nonsubfoveal and subfoveal GA, pegcetacoplan reduced the mean rate of change in GA area up to 32% versus projected sham. Year after year, the reductions in the mean rate of change in GA area increased, with up to a 42% reduction observed in eyes with nonsubfoveal GA in the PM-PM group compared with projected sham in the first year of GALE. An 18% reduction in new scotomatous points (P=0.0156) was observed with PM-PM at 36 months, highlighting a significant impact in a prespecified microperimetry analysis. Adverse events included 33 (4.5%) eyes with exudative AMD, 15 (1.9%) intraocular inflammation (classified as mild or moderate in severity), 1 (0.1%) ischemic optic neuropathy, and 1 (0.1%) infectious endophthalmitis. No events of vasculitis were reported.CONCLUSIONOver 36 months, pegcetacoplan continued to reduce GA growth with increasing efficacy over time and reduced formation of new scotomatous points. The safety profile of pegcetacoplan in the first 12 months of GALE was consistent with the prior 24-month OAKS and DERBY studies.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"35 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143885004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suprachoroidal drug delivery for VEGF suppression in wet AMD and other diseases with choroidal neovascularization.","authors":"Bryce Chiang,Yooree Grace Chung,Mark R Prausnitz","doi":"10.1016/j.ajo.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.020","url":null,"abstract":"PURPOSEChoroidal neovascularization caused by age-related macular degeneration, among other diseases, causes significant visual impairment. Intravitreal therapeutics inhibiting vascular endothelial growth factor (VEGF) signaling have shown excellent safety and efficacy in regressing choroidal neovascularization and improving vision. Current FDA-approved treatments deliver these drugs into the vitreous cavity, even though choroidal neovascularization originates from aberrant signaling in the choroid.DESIGNSystematic review METHODS: A literature search was conducted across PubMed and Google Scholar from inception up to December 31, 2024, focusing on studies investigating suprachoroidal delivery of anti-VEGF therapy. Randomized controlled trials, cohort studies, and case-control studies were included, while case reports and review articles were excluded.RESULTSFifteen peer-reviewed articles, 3 press releases, 6 conference abstracts and presentations, and 8 clinical trials were identified that relevant to the topic of suprachoroidal delivery of anti-VEGF therapy.CONCLUSIONThe suprachoroidal space is a potential space between the sclera and the choroid, which has recently become a route of delivery in an FDA-approved treatment. Notably, suprachoroidal delivery results in higher choroidal drug concentrations than intravitreal delivery. Promising results thus far have been seen with suprachoroidal delivery of VEGF-targeting therapies in clinical and pre-clinical studies; future work is needed to more-fully demonstrate safety and efficacy.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"67 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143884988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Penetrating Keratoplasty vs Lamellar Endothelial Keratoplasty in Iridocorneal Endothelial Syndrome: A Systematic Review and Meta-Analysis.","authors":"Gábor Tóth,Szilárd Váncsa,Tamás Kói,Kitti Kormányos,Péter Hegyi,Nóra Szentmáry","doi":"10.1016/j.ajo.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.017","url":null,"abstract":"PURPOSETo compare surgical outcomes following penetrating keratoplasty (PK), Descemet stripping endothelial keratoplasty (DSEK), and Descemet membrane endothelial keratoplasty (DMEK) in patients with iridocorneal endothelial (ICE) syndrome.DESIGNSystematic review and meta-analysis on individual patient data (IPD).METHODSPre-registration was performed in the PROSPERO database (registration number: CRD42024539444). Eligible studies from Embase, MEDLINE (via PubMed), and the Cochrane Central Register of Controlled Trials (CENTRAL) were retrieved up to April 24, 2024. Studies were included those reporting clinical outcomes after PK, DSEK, or DMEK- graft survival, best spectacle-corrected visual acuity (BSCVA) and endothelial cell density (ECD) - in people with ICE syndrome. Cochrane Handbook was followed for data extraction/ synthesis, and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) and the Joanna Briggs Institute Critical Appraisal Checklists were used to assess risk of bias. Meta-analyses were conducted using a random-effects model. Heterogeneity between studies was assessed using Q-test and I2 statistics.RESULTSNineteen of the 1963 screened studies were included in the meta-analysis. Multivariate pooled Kaplan-Meier curves with 95% confidence intervals, based on IPD from studies with at least 10 cases indicated that graft survival was better after PK compared to DSEK in patients with ICE syndrome. No significant difference (p=0.92) was found in BSCVA improvement between PK [-0.77 (95% CI, -1.45 to -0.09)], DSEK [-0.87 (95% CI, -1.35 to -0.39)] and DMEK [-0.85 (95% CI, -1.07 to -0.62)]. No significant differences in ECD were observed between DSEK and DMEK 6 (p=0.88) and 12 months (p=0.33) postoperatively. IPD analysis revealed no significant difference in graft survival between patients with and without anytime glaucoma (-0.04 ± 0.50 SEM; p=0.940) or cataract surgery (-0.45 ± 0.40 SEM; p=0.265).CONCLUSIONSPK demonstrated better graft survival compared to DSEK in patients with ICE, however, further research and additional evidence are needed to draw more definitive conclusions. Improvements in BSCVA were comparable across PK, DSEK and DMEK. Glaucoma surgery, whether performed before or after keratoplasty, appear to have no significant impact on graft survival.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"19 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BIRTH OF A CHANGE AGENT: THE FOUNDING OF 'WOMEN IN OPHTHALMOLOGY'.","authors":"Marjorie A Mosier,Penny Asbell,Jaqueline Lustgarten,Jane D Kivlin,Eve Higginbotham,Bronwyn Bateman","doi":"10.1016/j.ajo.2025.04.008","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.04.008","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"16 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}